Welcome to our dedicated page for HeartSciences news (Ticker: HSCSW), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. develops healthcare information technology for ECG/EKG management and AI-enabled cardiac analysis. News about the company centers on commercialization of MyoVista Insights, a cloud-native, device-agnostic ECG management and analysis platform, and MyoVista wavECG, a device designed to provide conventional ECG functionality while supporting AI-enabled solutions.
Recurring updates include platform interoperability, hospital and academic adoption, customer and reference-site activity, FDA-related developments for MyoVista wavECG, and quarterly financial and business updates. Company announcements also cover EHR workflow integration, ECG data management, clinical decision-support features, and investor communications tied to its Nasdaq-listed common stock and warrants.
HeartSciences, a company focused on AI-powered medical technology, announced the grant of Indian Patent Application 201817014481 for its MyoVista® Wavelet Technology. This patent expands its portfolio to 44 total granted patents, including nine in the US and 35 internationally, covering major markets such as China, Brazil, Canada, South Korea, Mexico, and key European nations. CEO Andrew Simpson highlighted the significance of this achievement, especially given India's large population of 1.4 billion people and the urgent need for better heart disease screening. Cardiovascular diseases are the leading cause of death in India, often presenting at an earlier age and with higher mortality rates compared to many other countries.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.